Close X
Attorney Spotlight

Learn about Richard Arnholt's diverse government contracts practice and why he chose to pursue a career in the legal field. Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2017, Pinnacle Financial Partners, Inc. (NASDAQ: PNFP) closed a $1.9 billion merger with BNC Bancorp (NASDAQ: BNCN) pursuant to which BNC merged with and into Pinnacle. With the completion of the transaction, Pinnacle becomes a Top 50 U.S. Bank. The merger will create a four state footprint concentrated in 12 of the largest urban markets in the Southeast. 

Bass, Berry & Sims has served Pinnacle as primary corporate and securities counsel for more than 15 years and served as counsel on the transaction. Our attorneys were involved in all aspects related to the agreement, including tax, employee benefits and litigation. 

Read more details about the transaction here.

Pinnacle Financial Partners logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Janelle Waack Comments on Exclusivity Terms for Biologic Drugs in Trans-Pacific Partnership Agreement

Media Mentions

October 6, 2015

Bass, Berry & Sims attorney Janelle Waack provided comment for a Modern Healthcare article outlining the details of the Trans-Pacific Partnership Agreement, a trade agreement between the U.S. and 11 countries. As part of the agreement, countries will extend data exclusivity for biologic medicines for five to eight years instead of the 12 years that the United States and the pharmaceutical industry recommended. The trade agreement next goes to the U.S. Congress, who will need to vote whether to accept the deal. As Janelle points out in the article, Congress will need to "carefully consider the impact on the pharmaceutical industry and smaller companies that are doing the ground level research, saying the agreement raises questions about whether they would continue 'to pursue these lines of research in view of what could be a more limited period of exclusivity.'"

The full article, "Trade Deal Disappoints Drugmakers, Consumer Groups," was published by Modern Healthcare on October 5, 2015 and is available online.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.